While the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has enough funds – albeit borrowed from other programs – to start a Phase I trial of an experimental Zika virus vaccine next month and even bring it to fruition, if Congress fails to allot new dollars within the next few weeks, a Phase IIb study may never get off the ground, or at least, be significantly delayed, the agency's chief said.
Anthony Fauci, director of the NIAID, told Scrip the agency expects to now initiate the Phase I study testing the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
